Latest News

Amgen to stop selling Repatha at higher list price, offer low-priced option exclusively

heart, doctor, cardiac

The biotech company had kept the drug available at the higher list price in order to give payers and pharmacy benefit managers time to adjust contracts and minimize supply chain disruptions.

Source link

Related posts

Patterson Companies to Present at the 2020 J.P. Morgan Healthcare Conference


Medical News Today: Depression: Gene-activating drug reverses symptoms in mice


Shirley Family Office Sends Letter to PLx Pharma (PLXP) Board of Directors


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy